Friday September 14

 |  Epidemiology and natural history of AAA
    Hans-Henning Eckstein, Rebecka Hultgren
  08.30  When is the prevalence too low to motivate continued screening? Sverker Svensjö presentation imad 2018
  08.38  The New Zealand AAA-specific risk scoring tool, Gregory Jones presentation imad 2018
  08.46  Aneurysm rupture is not simply a mechanical event: how so and what are the implications? Rao Vallabhaneni presentation imad 2018
  08.54  Female sex is not an independent risk factor for higher periprocedural mortality rates of AAAs - the nationwide Swedish DRG microdata from 2000-2016 on >50.000 cases, including socioeconomical aspects,
Rebecka Hultgren
  09.02  Why do women have higher operative mortality than men for aortic aneurysm repair? Janet Powell presentation imad 2018
  09.10  Do all 25-29 mm ectatic aortas progress to AAAs actually needing repair? Sverker Svensjö presentation imad 2018
  09.18  Short communication: blood glucose, diabetes and abdominal aortic aneurysm among 2 million screened individuals, Dylan Morris presentation imad 2018
  09.22  Short communication: should we screen women for abdominal aortic aneuvrysm, Pinar Ulug presentation imad 2018
  09.26  Short communication: the TAGA study: a new family study for the genetic analysis of aortic abdominal aneurysm, Maria Sabater-Lleal presentation imad 2018
  09.30  Discussion
  09.45  Frank Lederle lectures, Ronald Dalman
  10.05  Coffee break
    Ask to expert II (Nagelmackers room – Level 2)
    How can we avoid spinal cord ischemia during TEVAR/EVAR for Aortic aneurysms? John Elefteriades
    Case presentation : paraplesia, a rare complication of EVAR for AAA, Vincent Tchana-Sato
  |  Medical treatment of AAA
    Ronald Dalman, Anders Wanhainen
  10.35  AAA: is there a role for the prevention and therapy using antioxidants? Joël Pincemail presentation imad 2018
  10.45  Could metformin be a drug effective in limiting AAA growth and requirement for surgery: data from a large group of cohorts, Jonathan Golledge presentation imad 2018
  10.55  Ticagrelor and the inhibition of growth in small AAAs – results from a RCT, Anders Wanhainen
  11.05  The role of fish oil in the natural history of AAA, Jes Lindholt presentation imad 2018
  11.15  Hormone replacement therapy and AAA - A HUNT study based on 20.000 women, Rebecka Hultgren
  11.25  Role of resveratrol and the bone protein sclerostin in protection from AAA, Jonathan Golledge
  11.35  Cipro and the aorta - Fluoroquinolone attack? Bulat Ziganshin presentation imad 2018
  11.45  What diabetes can teach us about AAA? Ronald Dalman
  11.55  Short communication: final findings of the fenofibrate in the management of abdnominal aortic aneuvrysm (fame) - 2 trial, Joseph Moxon presentation imad 2018
  12.00  Discussion
  12.30  Lunch break
  |  EVAR & TEVA
    Colin Bicknell, Kakkhee Yeung
  13.53  The role of open surgery for AAA in the endovascular era, Franco Grego presentation imad 2018
  14.01  The effect of clinical, psychosocial and socio-demographic variables on mental and physical functioning after vascular surgery, Colin Bicknell presentation imad 2018
  14.09  The UK Complex Aneurysm study: an overview, Rao Vallabhaneni presentation imad 2018
  14.17  Endoleaks in EVAR, risk factors and prevention, Eric Allaire presentation imad 2018
  14.25  Wide proximal aortic neck in the outcome of EVAR, Athanasios Giannoukas presentation imad 2018
  14.33  Acute kidney injury after endovascular surgery: results from a pilot randomized controlled trial and a cohort study, Athanasios Saratzis presentation imad 2018
  14.41  Importance of changes in thoracic and abdominal aortic stiffness following stent graft implantation,
Christos Liapis
presentation imad 2018
  14.49  Prevention of stent graft migration after TEVAR: mathematical model, Milos Sladojevic presentation imad 2018
  14.57  Results of endurant study (follow-up and comparison with Ace study), Jean-Pierre Becquemin presentation imad 2018
  15.05  What do we know about AD risk factors for later problems? Jan Brunkwall presentation imad 2018
  15.13  Discussion
  15.30  Coffee break
    Ask to expert III (Nagelmackers room – Level 2)
    Spinal cooling catheter: new concept in paraplesia prevention, John Elefteriades
  |  Associations in aortic aneurysmal disease
    Thomas Bilfinger, Nicos Labropoulos
  16.05  Arterial aneurysms associated with the aorta, Nicos Labropoulos presentation imad 2018
  16.13  Is AAA a risk factor for neoplasia? Natzi Sakalihasan
  16.21  What is the association between AAA, hernia and simple renal cyst? Apostolos Tassiopoulos presentation imad 2018
  16.29  Incidence of AAA is higher in the patients with COPD and smoking - why? Thomas Bilfinger presentation imad 2018
  16.37  Are abdominal aortic aneurysms different in patients with and without concurrent athero-occlusive disease?
Jonathan Golledge
  16.45  Cardiovascular risk management in patients with small AAA, Matthew Bown
  16.53  Discussion
  |  Management of aortic graft infections
    Hans-Henning Eckstein, Rebecka Hultgren
  17.15  Endovascular repair is effective in emergency but definitive excisional graft removal is the aim for all infected aortic grafts and endografts, Colin Bicknell presentation imad 2018
  17.23  The place of allografts in the management of aortic graft infections, Evelyne Boesmans presentation imad 2018
  17.31  Treatment of vascular infection with arterial homografts: 27 years of experience at European Homograft Bank (EHB) in Brussels, Ramadan Jashari presentation imad 2018
  17.39  How to treat an infected aortic endograft by in-situ reconstruction with pericard tube grafts?
Hans-Henning Eckstein
presentation imad 2018
  17.47  Discussion
  18.15  Awards ceremony and adjournment